Sanket Koul

Dubai removes real estate investment limit for two-year investor visa

Experts laud timing of Dubai's move to ease investor visa norms, which could revive interest among Indian buyers amid recent geopolitical uncertainty

Canada approves DRL's Ozempic generic after months of regulatory logjam

DRL is the first company to receive market authorisation for a generic semaglutide injection in Canada. It is the first generic semaglutide to be approved in a G7 country

Anant Raj to enter Singapore data centre market with new subsidiary

The Delhi-based developer plans to set up a wholly owned subsidiary in Singapore to offer data centre and cloud services, marking its first overseas expansion amid rising demand

Centre sets eyes on heatwave management as higher temperatures grip India

Labour Ministry calls for urgent heatwave protection measures for workers

IHH-Daiichi case: Tokyo court concludes hearing, ruling on September 10

The deal was held up in court amid Daiichi Sankyo's long-running dispute with the Singh brothers over its purchase of Ranbaxy Laboratories more than a decade ago

West Asia crisis: Affordable housing may lose more ground amid rising costs

Rising input costs amid West Asia tensions may shrink affordable housing supply, as thin margins deter developers despite strong demand in urban India

Medtech backs India-NZ FTA, flags CDSCO exclusion as key regulatory gap

Medical device makers welcome India-NZ FTA for easing market access and exports, but flag absence of CDSCO in regulatory recognition framework as a key gap

Brazil rejects Dr Reddy's, Cipla GLP-1 generics on technical grounds

Brazil's regulator Anvisa rejects DRL and Cipla's generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Rising API prices from China and feedstock disruptions amid the West Asia crisis are tightening cost pressures on India's pharma sector despite temporary inventory buffers

Ammonia shortage: DoP to seek support from MoPNG, Fertilisers Dept

The Department of Pharmaceuticals plans to approach MoPNG and the Fertilisers Department to secure ammonia supplies for drugmakers amid shortages triggered by West Asia tensions

MNC medtech firms seek changes in local content norms for procurement

Multinational medtech firms have urged the Centre to revise local content calculations under PPOs, proposing inclusion of R&D and maintenance costs to widen eligibility in tenders

Centre revises DCGI recruitment rules, raises age limit to widen pool

The Centre has raised the age limit and broadened eligibility norms for appointing the Drug Controller General of India to address a shortage of qualified candidates

Lohia Worldspace eyes Delhi market entry, expansion in Moradabad in FY27

Lohia Worldspace plans Delhi entry with a Kirti Nagar high-rise and expands in Moradabad, targeting multiple projects and investments in FY27

Max Healthcare to add 1,200 beds in FY27, says Chairman Abhay Soi

Max Healthcare plans to expand capacity to 6,500 beds by FY27 and boost medical tourism through overseas offices and new facilities, including a 400-bed tower in Delhi

West Asia war drags India's March drug exports for first time in 3 years

On an FY basis, India's pharma exports remained flat at $31.11 billion in FY26, a 2.13 per cent rise from $30.47 billion in FY25

Signature Global to invest ₹2,890 crore in Tonino Lamborghini project

Signature Global has partnered Tonino Lamborghini to develop a branded residences project in Gurugram, with a planned investment of Rs 2,890 crore and expected GDV of Rs 4,000 crore

Strait of Hormuz crisis poses threat to India's luxury housing market

Developers stare at delayed imports of key materials, higher costs of imports and potential delay in construction timelines

Parliamentary panel pulls up HealthMin over drug scheme funding gaps

Panel flags funding discontinuity in drug regulation scheme, urges swift SSDRS 2.0 approval and decentralisation of medical device clearances to ease bottlenecks and improve oversight

Medtech industry split over Centre's move on standard device testing fees

Medtech firms are split over draft norms on standardised testing fees, with some backing transparency and others warning of higher compliance burden for low-risk devices

Drug regulator may retain GMP relaxations in Schedule M for select products

DTAB recommends continuing GMP exemptions under revised Schedule M for disinfectants, medical gases and gelatin capsules, citing limited relevance of strict norms